Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy

Relationships between patient characteristics, ofatumumab pharmacokinetics, and treatment outcomes were investigated in this phase 2 trial of ofatumumab plus fludarabine and cyclophosphamide (FC) in untreated chronic lymphocytic leukemia. Patients were randomized 1:1 to receive 500 or 1000 mg ofatum...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Leuk Lymphoma
Autors principals: Jewell, Roxanne C., Kipps, Thomas J., Dürig, Jan, Griskevicius, Laimonas, Stilgenbauer, Stephan, Smolej, Lukáš, Mayer, Jiří, Hess, Georg, Hernandez-Ilizaliturri, Francisco J., Padmanabhan-Iyer, Swaminathan, Fang, Lei, Goldstein, Nancy, Gorczyca, Michele, Gupta, Ira, Lisby, Steen, Wierda, William G.
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7063681/
https://ncbi.nlm.nih.gov/pubmed/26763349
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2015.1128540
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars